CClinicalTrials.gg
CompletedNCT03706417Updated Sep 12, 2025Results posted

Telemedicine to Improve Use of Therapeutic Hypothermia in Rural Settings

An interventional study of Telemedicine consult in Neonatal Encephalopathy, sponsored by MaineHealth. Completed at 1 site in United States. Open to participants aged Up to 6 Hours. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by MaineHealth · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
115
Allocation
Not applicable
Ages
Up to 6 Hours
Sex
All
01

Study summary

This pilot intervention trial will assess the feasibility of a live consultation between community hospital providers and tertiary care providers employing a novel teleconsult platform, Maine Neonatal Encephalopathy Teleconsult (Maine NET), on the time to initiation of therapeutic hypothermia (TH) for 35 infants born in community hospitals in Maine compared with matched historical controls. Community hospital providers and tertiary care center provider satisfaction with the Maine NET platform will also be assessed. The hypothesis is that immediately available expert assessment via a teleconsult platform will promote earlier implementation of TH and be associated with high levels of provider satisfaction.

Read the detailed description

The study will recruit a total of 125 infants from the participating centers and anticipate that 35 of these subjects will be treated with therapeutic hypothermia and be utilized for the comparative analysis to historical controls. Not all infants recruited and provided a Maine NET consultation will be treated with TH and to have an adequate sample size to make statistical comparisons with historical controls we need to enroll more than 35 participants to ensure 35 have been treated with TH for the comparative analysis.

In a secondary qualitative study, clinicians who completed Maine NET consults through the above clinical trial were interviewed about their experience with the consult. This secondary study will recruit up to 20 clinicians who completed a consult in this clinical trial.

02

Conditions studied

  • Neonatal Encephalopathy

Browse trials for

Keywords

  • Hypothermia, Induced
  • Telemedicine
  • Hospitals, Community
03

Who can participate

Ages eligible
Up to 6 Hours
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Infants included in this study will be born at a community hospital, will be in either high or moderate risk, will be younger than 6 hours of age at the time of the consultation and the decision will have been made to treat with TH. High risk infants will be defined as an umbilical cord pH of less than or equal to 7.0 or 5 minute APGAR score of less than or equal to 5 or a need for resuscitation (including respiratory support or chest compressions) or an abnormal exam (which may include flaccid tone, poor suck reflex or poor response to stimulation) or seizures at less than 6 hours of life. Moderate risk infants will be defined as an umbilical cord pH of less than or equal to 7.2 but greater than 7.0 or 5 minute APGAR score of less than 7 but greater than 5 or a perinatal event (such as placental abruption, uterine rupture, cord prolapse, or fetal-maternal hemorrhage) or an abnormal exam (which may include a hyper-alert state).

Exclusion criteria

Exclusion Criteria:

Infants older than 6 hours at the time Maine NET is requested and infants for whom TH is not an appropriate therapy (e.g. due to premature birth or moribund status) will be excluded.

04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    Telemedicine

    Babies that received telemedicine consult intervention.

    Diagnostic Test: Telemedicine consult

Interventions

  • Diagnostic testTelemedicine consult

    Utilizing telemedicine in community hospital for earlier identification of symptoms of neonatal encephalopathy.

05

What researchers measure

Primary outcomes

  1. Time to Initiation of Therapeutic Hypothermia

    Time to initiation of therapeutic hypothermia

    Time frame: First 6 hours of life

06

Results

Posted Sep 12, 2025

Participant flow

Participant flow — Overall Study
MilestoneTelemedicine
Started115
Completed115
Not completed0

Outcome measures

PrimaryTime to Initiation of Therapeutic Hypothermia

Time to initiation of therapeutic hypothermia

Time frame:
First 6 hours of life
Reported as:
Mean · hours
Time to Initiation of Therapeutic Hypothermia
hoursTelemedicine
Time to Initiation of Therapeutic Hypothermia4.5 (3.5 to 5.0)

Adverse events

Collected over Duration of the telemedicine consultation (10-30 minutes). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Telemedicine0/113 (0%)0/113 (0%)0/113 (0%)

Baseline characteristics

Age, Customized
Age, Customized(Participants)Telemedicine
0-6 hours115
Sex: Female, Male
Sex: Female, Male(Participants)Telemedicine
Female44
Male71
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Telemedicine
Hispanic or Latino1
Not Hispanic or Latino101
Unknown or Not Reported13
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Telemedicine
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American4
White97
More than one race2
Unknown or Not Reported11
Region of Enrollment
Region of Enrollment(participants)Telemedicine
United States115
07

Study locations

1 site
  • Maine Medical Center
    Portland, Maine 04102, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Mar 29, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03706417
Lead sponsor
MaineHealth
Responsible party
Alexa Craig (Associate Professor of Pediatrics, MaineHealth) — Principal investigator
First posted
Oct 16, 2018
Start date
Apr 30, 2018
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023
Results posted
Sep 12, 2025
Last update
Sep 12, 2025

Study contacts

Alexa Craig, MD
principal investigator · MaineHealth

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion